Turnstone Biologics Corp

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Turnstone Biologics Corp. operates as a clinical stage biotechnology company. It engages in the business of developing and commercializing therapeutics. The company is focused on developing new medicines to treat and cure patients with solid tumors. Turnstone Biologics was founded in 2015 and is headquartered in La Jolla, CA.

Turnstone's next-generation Selected TIL technology is designed to selectively expand the most potent tumor-reactive T cells for treatment of solid tumors Results further support the continued clinical advancement of TIDAL-01, currently being evaluated in Phase 1 trials SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced it will be presenting two posters highlighting preclinical data on methods for TIL selection at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6-10, 2024 in Houston, Texas. “We remain confident that delivering a TIL-based product with a higher proportion of tumor-reactive T cells is the key to extending the clinical application of TILs across a broader range of solid tumors,” said David Stojdl, Ph.D.

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Turnstone Biologics Corp. TSBX stock is trading lower after the company released initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite-stable colorectal cancer (MSS mCRC) on Thursday.

Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study

Turnstone Biologics (NASDAQ: TSBX ) stock is falling on Thursday following the release of the clinical-stage biotechnology company's earnings report. The bad news pulling TSBX stock down today is the company's diluted earnings per share of -92 cents.

Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?

Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.

Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line patient with progression free survival extending beyond one year Favorable tolerability profile and demonstrated manufacturing success Product characterization and translational data support biological hypothesis for Selected TILs SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported positive initial data from its Phase 1 STARLING trial of TIDAL-01 in metastatic microsatellite stable colorectal cancer (“MSS mCRC”). Turnstone's Phase 1 STARLING trial is an ongoing muti-site, first-in-human, non-randomized, open label, single-dose study, and is evaluating the safety, tolerability, and clinical activity of TIDAL-01.

Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer

LAVA Therapeutics NV

Milestone Pharmaceuticals Inc

Rallybio Corp

Are you looking for stocks to buy with low price tags?

4 Stocks Under $5 To Buy Now

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the first quarter ended March 31, 2024, and provided recent business highlights. “We are excited about the therapeutic potential of our pipeline of next-generation Selected TIL therapies,” said Sammy Farah, M.B.A.

Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights

SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.

Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference

SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors.

Turnstone Biologics Appoints William Waddill to its Board of Directors

Lead program, TIDAL-01, advancing in Phase 1 trials with initial clinical data expected in mid-2024 Promising preclinical data highlighting Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided recent business highlights.

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

SAN DIEGO, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that members of its senior management team will participate in the following investor conferences: TD Cowen 44 th Annual Global Health Care Conference       Type:       Presentation and one-on-one investor meetings Speaker:   Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer Date:   Wednesday, March 6, 2024 Presentation Time:   2:10pm ET / 11:10am PT Location:   Boston, MA       Leerink Partners Global Biopharma Conference 2024       Type:Date:Location:   One-on-one investor meetingsWednesday, March 13, 2024Miami, FL A live webcast of the presentation may be accessed on the Events page of Turnstone's Investor Relations website at https://ir.turnstonebio.com, where a replay will also be available for a limited period.

Turnstone Biologics to Participate in Upcoming Investor Conferences

SAN DIEGO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced with sadness that P. Joseph Campisi, Jr., Esq, the Company's Chief Legal Officer, passed away on February 1, 2024, following a prolonged battle with cancer.

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Dr. Sammy Farah, President and CEO of Turnstone, will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference in New York.

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

– Promising preclinical data showcasing Turnstone's novel Selected TIL programs for solid tumors presented at SITC 2023 – – Lead program, TIDAL-01, advancing and on track in two Phase 1 trials with initial clinical data expected mid-2024 – – Upsized IPO extends runway into Q2 2025 and supports advancement of pipeline through key milestones – – Further strengthened Scientific Advisory Board with appointment of internationally recognized cancer immunotherapy expert, Dr. Jeffrey S. Weber – SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the quarter ended September 30, 2023, and provided recent business highlights.

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Posters showcase Turnstone's novel Selected TIL programs which are designed to selectively expand the most potent tumor-reactive T cells for solid tumors.

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Internationally recognized cancer immunotherapy thought leader, Dr. Weber, will help guide Turnstone's continued advancement of its Selected TIL therapies

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

SAN DIEGO, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced four posters reporting preclinical data for Turnstone's Selected TIL therapies will be presented at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (SITC).

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Scilex Holding Co

Sight Sciences

Tenaya Therapeutic

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Could Lead To Your Biggest Gains In Q3

SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent business highlights.

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Financial). This article provides an in-depth analysis of the transaction, profiles of both FMR LLC (Trades, Portfolio) and Turnstone Biologics Corp, and the potential implications of this acquisition on the market.

FMR LLC Acquires Significant Stake in Turnstone Biologics Corp

Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said it sold 6.67 million shares in the IPO, up from a previously expected offering of 5.80 million shares.

Turnstone Biologics set to go public as upsized $80 million IPO pricing at low end of expected range

SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to tumor-infiltrating lymphocyte (TIL) therapy, today announced the pricing of its upsized initial public offering of 6,666,667 shares of common stock at a price to the public of $12.00 per share. All shares of common stock are being offered by Turnstone. The gross proceeds to Turnstone from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Turnstone, are expected to be $80.0 million. In addition, Turnstone has granted the underwriters a 30-day option to purchase up to an additional 1,000,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agreements, so I'm cautious about the firm's prospects.

IPO Update: Turnstone Biologics Readies $75 Million IPO Plan

Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The company would raise $81.2 million at the top of that range at a valuation of $298 million.

Turnstone Biologics to offer 5.8 million shares in planned IPO priced at $12 to $14 each

Turnstone Biologics has filed to raise $86 million in a U.S. IPO, although the final figure may differ. The company is developing treatment candidates for various cancers. TSBX is still in Phase 1 safety trials for its lead candidate; the firm has notable life science investors and collaboration agreements with major pharmaceutical companies.

News for Turnstone Biologics Corp Stock (TSBX)